Last reviewed · How we verify

Labor pain — Treatment Landscape & Competitive Intelligence

Labor pain (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Labor pain, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Opana Er OXYMORPHONE Endo Opioid Agonist Mu-type opioid receptor 1959-01-01
Meperidine Hydrochloride Preservative Free Meperidine Hydrochloride Pfizer Opioid Agonist Mu-type opioid receptor 1942-01-01
Pethidin Pethidin Ain Shams University Solute carrier family 22 member 1, Glutamate receptor ionotropic, NMDA 3A, Kappa-type opioid receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 2 drugs in Labor pain
  2. Ain Shams University · 1 drug in Labor pain
  3. Endo · 1 drug in Labor pain
  4. Pfizer · 1 drug in Labor pain

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Labor pain:

Cite this brief

Drug Landscape (2026). Labor pain — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/labor-pain. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing